Algeta appoints senior vp, Protein Therapeutics
New role created to drive development of Thorium platform
Abrahmsen takes responsibility for the development of Oslo-based Algeta’s Thorium platform and for building and overseeing the preclinical development of a pipeline of alpha-pharmaceutical candidates based on tumour-targeted thorium-227 conjugates.
This builds on the progress made with Alpharadin, an alpha-pharmaceutical being developed in a phase III trial by Algeta and Bayer Schering Pharma for treating bone metastases arising from castration-resistant prostate cancer.
Abrahmsen has joined Algeta from Affibody, a Swedish company developing proprietary targeting molecules for therapeutic and diagnostic purposes, where he held the position of chief scientific officer since 2004. Prior to this he worked for Genentech and Pharmacia, where he established their phage display and antibody cloning capabilities.
You may also like
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection